Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
JY509 in Relapsed or Refractory Pediatric B-ALL
NCT07406178Phase 1Not yet recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Jan 2026
- Primary completion
- Jan 2029
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
01
Overview
Phase 1, open-label, single-arm trial of JY509 in B cell acute lymphoblastic leukemia (B-ALL), sponsored by Institute of Hematology and Blood Diseases Hospital. Primary endpoint: Adverse Events at 1 year. Planned start Jan 2026; status: not yet recruiting.
02
Drugs
JY509
03
Conditions
B cell acute lymphoblastic leukemia (B-ALL)
Beyond the preview
Go deeper on NCT07406178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07406178.